Integrated and Long-Term Safety Analysis of Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：13 / 14
页数：2
相关论文
共 50 条
  • [1] Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Coutre, Steven
    Byrd, John C.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Devereux, Stephen
    Robak, Tadeusz
    Kipps, Thomas J.
    Schuh, Anna
    Moreno, Carol
    Furman, Richard R.
    Burger, Jan
    O'Dwyer, Michael
    Ghia, Paolo
    Valentino, Rudolph
    Suzuki, Samuel
    Ninomoto, Joi
    James, Danelle F.
    O'Brien, Susan M.
    [J]. BLOOD, 2016, 128 (22)
  • [2] Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Jaglowski, Samantha M.
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Maddocks, Kami J.
    Woyach, Jennifer A.
    Blum, Kristie A.
    Greyer, Michael R.
    Geyer, Susan Michelle
    Heerema, Nyla A.
    Lozanski, Gerard
    Stefanos, Mona
    Hall, Nathan
    Nagar, Veena
    Munneke, Brian
    West, Jamie-Sue
    Neuenburg, Jutta K.
    James, Danelle F.
    Johnson, Amy J.
    Byrd, John C.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S206 - S207
  • [3] Characteristics and Clinical Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Long-Term Ibrutinib Treatment in the RESONATE-2 Study
    Woyach, Jennifer A.
    Barr, Paul M.
    Kipps, Thomas J.
    Barrientos, Jacqueline C.
    Ahn, Inhye E.
    Ghia, Paolo
    Girardi, Vincent
    Hsu, Emily
    Jermain, Mandy
    Burger, Jan A.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S278 - S278
  • [4] Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)
    O'Brien, Susan M.
    Jones, Jeffrey A.
    Furman, Richard R.
    Coutre, Steven E.
    Flinn, Ian W.
    Burger, Jan A.
    Blum, Kristie A.
    Sharman, Jeff P.
    Wierda, William G.
    Zhao, Weiqiang
    Heerema, Nyla A.
    Johnson, Amy J.
    Tran, Anh
    Zhou, Cathy
    Bilotti, Elizabeth
    James, Danelle F.
    Byrd, John C.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S206 - S206
  • [5] Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Analysis of 2028 patients
    Tsimberidou, A. M.
    Wen, S.
    O'Brien, S.
    McLaughlin, P.
    Wierda, W. G.
    Kantarjian, H.
    Lerner, S.
    Strom, S.
    Freireich, E. J.
    Medeiros, L.
    Keating, M. J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 196 - 196
  • [6] Are chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) the same disease?
    Keating, M
    McLaughlin, P
    Tsimberidou, A
    O'Brien, S
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 46 - 47
  • [7] Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Case Study
    Nanni, Danielle
    [J]. JOURNAL OF DIAGNOSTIC MEDICAL SONOGRAPHY, 2024, 40 (03) : 289 - 293
  • [8] Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Kipps, Thomas J.
    Fraser, Graeme
    Coutre, Steven
    Brown, Jennifer R.
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Byrd, John C.
    O'Brien, Susan M.
    Dilhuydy, Marie-Sarah
    Devereux, Stephen
    Jaeger, Ulrich
    Moreno, Carol
    Cramer, Paula
    Stilgenbauer, Stephan
    Chanan-Khan, Asher A.
    Mahler, Michelle
    Salman, Mariya
    Cheng, Mei
    Londhe, Anil
    Ninomoto, Joi
    Howes, Angela
    James, Danelle
    Hallek, Michael
    [J]. CANCER RESEARCH, 2017, 77
  • [9] Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib
    Rogers, Kerry A.
    Woyach, Jennifer A.
    Andritsos, Leslie A.
    Awan, Farrukh
    Blum, Kristie A.
    Flynn, Joseph M.
    Jaglowski, Samantha
    Lozanski, Gerard
    Maddocks, Kami J.
    Byrd, John C.
    Jones, Jeffrey A.
    [J]. BLOOD, 2014, 124 (21)
  • [10] Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
    Finnes, Heidi D.
    Chaffee, Kari G.
    Call, Timothy G.
    Ding, Wei
    Kenderian, Saad S.
    Bowen, Deborah A.
    Conte, Michael
    McCullough, Kristen B.
    Merten, Julianna A.
    Bartoo, Gabriel T.
    Smith, Matthew D.
    Leis, Jose
    Chanan-Khan, Asher
    Schwager, Susan M.
    Slager, Susan L.
    Kay, Neil E.
    Shanafelt, Tait D.
    Parikh, Sameer A.
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1376 - 1383
12345